223 related articles for article (PubMed ID: 32266708)
1. Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.
Iaccarino G; Borghi C; Cicero AFG; Ferri C; Minuz P; Muiesan ML; Mulatero P; Mulè G; Pucci G; Salvetti M; Savoia C; Sechi LA; Volpe M; Grassi G
High Blood Press Cardiovasc Prev; 2020 Apr; 27(2):105-108. PubMed ID: 32266708
[TBL] [Abstract][Full Text] [Related]
2. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
3. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
[TBL] [Abstract][Full Text] [Related]
4. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.
Albini A; Di Guardo G; Noonan DM; Lombardo M
Intern Emerg Med; 2020 Aug; 15(5):759-766. PubMed ID: 32430651
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
Patel AB; Verma A
JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485
[No Abstract] [Full Text] [Related]
6. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.
Bravi F; Flacco ME; Carradori T; Volta CA; Cosenza G; De Togni A; Acuti Martellucci C; Parruti G; Mantovani L; Manzoli L
PLoS One; 2020; 15(6):e0235248. PubMed ID: 32579597
[TBL] [Abstract][Full Text] [Related]
7. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
Guo X; Zhu Y; Hong Y
Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694
[No Abstract] [Full Text] [Related]
8. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
9. [Scientific statement on using of renin angiotensin system blockers in patients with cardiovascular disease and COVID-19].
;
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jul; 48(7):565-566. PubMed ID: 32842268
[TBL] [Abstract][Full Text] [Related]
10. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
Mancia G; Rea F; Ludergnani M; Apolone G; Corrao G
N Engl J Med; 2020 Jun; 382(25):2431-2440. PubMed ID: 32356627
[TBL] [Abstract][Full Text] [Related]
11. Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension.
Iaccarino G; Grassi G; Borghi C; Ferri C; Salvetti M; Volpe M;
Hypertension; 2020 Aug; 76(2):366-372. PubMed ID: 32564693
[TBL] [Abstract][Full Text] [Related]
12. COVID-19, hypertension, and renin-angiotensin-aldosterone system inhibitors: Much ado about nothing or real problem to be solved?
Tadic M; Cuspidi C
J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1984-1986. PubMed ID: 32951351
[No Abstract] [Full Text] [Related]
13. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
Vázquez-Cornejo E
Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690
[TBL] [Abstract][Full Text] [Related]
14. Related molecular mechanisms of COVID-19, hypertension, and diabetes.
Akkus E; Sahin M
Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E881. PubMed ID: 32479159
[No Abstract] [Full Text] [Related]
15. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities.
Patoulias D; Katsimardou A; Stavropoulos K; Imprialos K; Kalogirou MS; Doumas M
Curr Hypertens Rep; 2020 Sep; 22(11):90. PubMed ID: 32910274
[TBL] [Abstract][Full Text] [Related]
16. Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service.
Kim J; Kim DW; Kim KI; Kim HB; Kim JH; Lee YG; Byeon KH; Cheong HK;
J Korean Med Sci; 2020 Jun; 35(25):e232. PubMed ID: 32597045
[TBL] [Abstract][Full Text] [Related]
17. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers.
Singh AK; Gupta R; Misra A
Diabetes Metab Syndr; 2020; 14(4):283-287. PubMed ID: 32283499
[TBL] [Abstract][Full Text] [Related]
18. Facts and reflections on COVID-19 and anti-hypertensives drugs.
Marin GH
Drug Discov Ther; 2020 May; 14(2):105-106. PubMed ID: 32213760
[TBL] [Abstract][Full Text] [Related]
19. Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection.
Salah HM; Calcaterra G; Mehta JL
J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):503-507. PubMed ID: 32748634
[TBL] [Abstract][Full Text] [Related]
20. Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.
Furuhashi M; Moniwa N; Takizawa H; Ura N; Shimamoto K
Hypertens Res; 2020 Aug; 43(8):837-840. PubMed ID: 32433641
[No Abstract] [Full Text] [Related]
[Next] [New Search]
